Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Sanofi’s sale of its $17bn consumer health ... The medicine is so popular that most paracetamol products are referred to as Doliprane, regardless of the manufacturer. In addition, Opella ...

Major pharmaceutical products and medicines have jumped in prices despite and executive order by President Bola Tinubu, ...

The sale of the Sanofi shares will “optimize” L’Oreal’s balance sheet following recent acquisitions and further diversify its financing sources, the maker of shampoo and cosmetics brands ...

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical companies in order to continue successfully introducing new products in major markets ...